Quarterly report pursuant to Section 13 or 15(d)

3. Significant Strategic Collaborations - Related Parties

v3.7.0.1
3. Significant Strategic Collaborations - Related Parties
6 Months Ended
Jun. 30, 2017
Significant Strategic Collaborations - Related Parties  
Significant Strategic Collaborations - Related Parties

The Company has entered into various research, development, license and supply agreements with the Company’s controlling stockholder PJSC Pharmsynthez (“Pharmsynthez”) and SynBio LLC (“SynBio”), which is a wholly owned subsidiary of Pharmsynthez, Serum Institute of India (“Serum Institute”) and Shire plc (“Shire”). The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through June 30, 2017. No amounts were recognized as revenue related to these agreements during the six months ended June 30, 2017 or 2016.